Evotec Full Year 2023 Earnings: EPS Misses Expectations

Evotec (ETR:EVT) Full Year 2023 Results

Key Financial Results

• Revenue: €781.4m (up 4.0% from FY 2022).
• Net loss: €83.9m (loss narrowed by 52% from FY 2022).
• €0.47 loss per share (improved from €0.99 loss in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Evotec EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 55%.

Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.

Performance of the market in Germany.

The company's shares are down 32% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 1 warning sign for Evotec that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.